Corvus Pharmaceuticals (CRVS) Research & Development (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Research & Development of $5.0 million for Q1 2026, down 32.34% year-over-year from $7.5 million in Q1 2025, and down 40.35% quarter-over-quarter from $8.5 million in Q3 2025.
Corvus Pharmaceuticals (CRVS) Research & Development (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Research & Development history runs 12 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Research & Development fell 32.34% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $28.8 million (up 65.14% YoY), while the FY2023 annual figure was $16.5 million, down 32.46% from the prior year.
- Research & Development for Q1 2026 stood at $5.0 million, down from $8.5 million in the prior quarter.
- The five-year high for Research & Development was $10.4 million in Q3 2022, with the low at $665000.0 in Q1 2024.
- The 5-year median for Research & Development is $4.9 million (2022), against an average of $5.3 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development tumbled 85.52% in 2024, then jumped 1020.75% in 2025.
- Corvus Pharmaceuticals' Research & Development stood at $4.1 million in 2022, then fell by 1.99% to $4.0 million in 2023, then jumped by 30.58% to $5.2 million in 2024, then soared by 61.89% to $8.5 million in 2025, then slumped by 40.35% to $5.0 million in 2026.
- Business Quant data shows CRVS's Research & Development at $5.0 million in Q1 2026, $8.5 million in Q3 2025, and $7.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 15.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.96 Mn |
| Mar 31, 2026 | 5.04 Mn |
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.87 Mn |
| Mar 31, 2025 | 7.45 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Mar 31, 2024 | 665,000.00 |
| Dec 31, 2023 | 4.00 Mn |
| Sep 30, 2023 | 3.97 Mn |
| Jun 30, 2023 | 3.97 Mn |
| Mar 31, 2023 | 4.59 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 10.37 Mn |
| Jun 30, 2022 | 4.92 Mn |
| Mar 31, 2022 | 5.10 Mn |
| Dec 31, 2021 | 4.79 Mn |
| Sep 30, 2021 | 6.99 Mn |
| Jun 30, 2021 | 9.11 Mn |
| Mar 31, 2021 | 8.23 Mn |